drugset
drugset / Trial / NCT03797391

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

NCT03797391 ↗

Phase 1/2 Unknown 186 enrolled Shanghai EpimAb Biotherapeutics Co., Ltd. Covance · collab
NaSequentialOpen-labelTreatment

Summary

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

Timeline

Start
2018-12-13
Primary completion
2025-03-14
Completion
2026-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BAFISONTAMAB Monoclonal antibody 100 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 200 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 350 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 500 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 700 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 900 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 1200 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 1600 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 2100 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 2700 mg Intravenous
Subject BAFISONTAMAB Monoclonal antibody 3000 mg Intravenous

Indications

metastatic neoplasm non-small cell lung carcinoma